H.E.L Group expands range of BioXplorer bioreactors to support bioprocess development

H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimization, safety, and scale-up, today expanded its BioXplorer range with the introduction of two new automated parallel bioreactors: BioXplorer 400XL and BioXplorer 400P. The new systems will further enable the efficient and cost-effective development and optimization of bioprocesses.

The BioXplorer 400P is designed for use at pressures up to 10 bar, allowing for increased cell density and product yields. Optimized for syngas fermentation, the BioXplorer 400P combines easy to use software with modular hardware to give complete control of four high-pressure bioprocesses simultaneously. The BioXplorer 400 XL features 8 configurable bioreactors, which can be controlled independently or in parallel.

Its modular design allows accurate and precise additions of liquids and gases, controlled by up to four sets of peristaltic pumps and up to two sets of mass flow controllers respectively, with software enabling control of all eight bioprocesses at once. Both bioreactors are available for use with either magnetic or direct agitation, to support enhanced cell densities and product yield.

The full range of H.E.L bioreactor systems allow automated, parallel experimentation in sizes ranging from 50 mL to 5 L, with applications in research into gas fermentation and bio-production at a bench-scale. Ideal for small-scale process development and cell line/strain screening, the flexible and adaptable bioreactors are suitable for research, screening, and optimization investigations.

 “Our flexible bioreactor systems help our customers gain more knowledge about their bioprocesses earlier in their development and so make better decisions, resulting in bioprocess development which is faster and more productive. The introduction of the new BioXplorer 400P and BioXplorer 400XL further increases our automated parallel bioreactor offering, doubling volume capabilities with highly configurable and readily upgradable systems.”

Louise Madden, CEO at H.E.L Group

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    H.E.L Group. (2023, June 09). H.E.L Group expands range of BioXplorer bioreactors to support bioprocess development. News-Medical. Retrieved on April 26, 2024 from https://www.news-medical.net/news/20230608/HEL-Group-expands-range-of-BioXplorer-bioreactors-to-support-bioprocess-development.aspx.

  • MLA

    H.E.L Group. "H.E.L Group expands range of BioXplorer bioreactors to support bioprocess development". News-Medical. 26 April 2024. <https://www.news-medical.net/news/20230608/HEL-Group-expands-range-of-BioXplorer-bioreactors-to-support-bioprocess-development.aspx>.

  • Chicago

    H.E.L Group. "H.E.L Group expands range of BioXplorer bioreactors to support bioprocess development". News-Medical. https://www.news-medical.net/news/20230608/HEL-Group-expands-range-of-BioXplorer-bioreactors-to-support-bioprocess-development.aspx. (accessed April 26, 2024).

  • Harvard

    H.E.L Group. 2023. H.E.L Group expands range of BioXplorer bioreactors to support bioprocess development. News-Medical, viewed 26 April 2024, https://www.news-medical.net/news/20230608/HEL-Group-expands-range-of-BioXplorer-bioreactors-to-support-bioprocess-development.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.